print_label | resize_label


The questions in this section may arise when speaking with parents and caregivers about respiratory syncytial virus (RSV), Synagis, and Cradle with Care℠.

What is RSV and when does RSV season begin and end?

How serious is RSV disease?

How easy is it to catch RSV?

What are the signs and symptoms of a severe RSV infection?


What is Synagis?

Is Synagis a vaccine?

What are the side effects of Synagis?

How do I report an adverse event?

How many Synagis shots does a high-risk baby need?

If a high-risk baby looks healthy, are monthly Synagis shots still necessary?

Will high-risk babies need Synagis for a second RSV season?

What should I do if insurance won’t cover Synagis?


What is the benefit of the program for parents/caregivers?

How do parents/caregivers sign up for the Cradle with Care program?

How do Spanish-speaking parents/caregivers enroll?

Do parents/caregivers have to enroll in Cradle with Care if their child is receiving Synagis?

What do the appointment reminders tell parents/caregivers to do?

Where can parents/caregivers receive information on financial assistance?

If parents/caregivers want to stop receiving information, can they opt out?

Important Safety Information

Synagis® (palivizumab) is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease. Safety and efficacy were established in children with bronchopulmonary dysplasia (BPD), infants with a history of premature birth (≤35 weeks gestational age), and children with hemodynamically significant congenital heart disease (CHD). The recommended dose of Synagis is 15 mg/kg of body weight given monthly by intramuscular injection. The first dose of Synagis should be administered prior to commencement of the RSV season and the remaining doses should be administered monthly throughout the RSV season. Children who develop an RSV infection should continue to receive monthly doses throughout the RSV season.

The efficacy of Synagis at doses less than 15 mg/kg, or of dosing less frequently than monthly throughout the RSV season, has not been established.

Synagis is contraindicated in children who have had a previous significant hypersensitivity reaction to Synagis. Cases of anaphylaxis and anaphylactic shock, including fatal cases, have been reported following initial exposure or re-exposure to Synagis. Other acute hypersensitivity reactions, which may be severe, have also been reported on initial exposure or re-exposure to Synagis. The relationship between these reactions and the development of antibodies to Synagis is unknown. If a significant hypersensitivity reaction occurs with Synagis, its use should be permanently discontinued. If a mild hypersensitivity reaction occurs, clinical judgment should be used regarding cautious readministration of Synagis. As with any intramuscular injection, Synagis should be given with caution to children with thrombocytopenia or any coagulation disorder. Palivizumab may interfere with immunological-based RSV diagnostic tests, such as some antigen detection-based assays.

Adverse reactions occurring greater than or equal to 10% and at least 1% more frequently than placebo are fever and rash. In post-marketing reports, cases of severe thrombocytopenia (platelet count <50,000/microliter) and injection site reactions have been reported.

Please see full Prescribing Information for Synagis, including Patient Information.